Literature DB >> 12639300

Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: methods and evidence for nonviral mRNA gene delivery to the central nervous system.

Dua M Anderson1, Leon L Hall, Anitha R Ayyalapu, Van R Irion, Michael H Nantz, James G Hecker.   

Abstract

Clinical applications of gene therapy require advances in gene delivery systems. Although numerous clinical trials are already underway, the ultimate success of gene therapies will depend on gene transfer vectors that facilitate the expression of a specific gene at therapeutic levels in the desired cell populations without eliciting cytotoxicity. In clinical applications for which transient expression is desirable, mRNA delivery is of particular interest. We have shown cationic lipid-mediated mRNA delivery to be feasible, efficient, and reproducible in vitro. mRNA delivery to the cerebrospinal fluid (CSF) in vivo would provide a means of vector distribution throughout the central nervous system (CNS). This study examined the functional integrity and protection from degradation of mRNA/cationic complexes (lipoplexes) in human cerebrospinal fluid (hCSF) in vitro and expression of these lipoplexes in vivo. Results obtained from gel electrophoresis indicate that cationic lipids protect mRNA transcripts from RNases in hCSF for at least 4 hr. This is in contrast to the total disappearance of nonlipid-complexed mRNA in less than 5 min. We confirmed the importance of RNase activity by incubating mRNA transcripts encoding luciferase or green fluorescent protein (GFP) in hCSF to which RNase inhibitors had been added. After incubation, these solutions were used to transfect Chinese hamster ovary (CHO) cells in vitro. Next, assays for both GFP and luciferase were used to demonstrate functional integrity and translation of the mRNA transcripts. Finally, we delivered in vitro transcribed mRNA vectors encoding for Hsp70 and luciferase to the lateral ventricle of the rat in a series of preliminary in vivo experiments. Initial immunohistochemistry analysis demonstrates that the distribution, uptake, and expression of reporter sequences using lipid-mediated mRNA vector delivery is extensive, as we earlier reported using similar methods with DNA vectors but that the expression may be less intense. Expression was noted in coronal sections throughout the rat brain, confirming the potential for lipid-mediated mRNA delivery to the CNS. These findings confirm that complexing mRNA with cationic lipid before exposure to CSF confers protection against RNase activity, facilitating distribution, cellular uptake, and expression of mRNA delivered into the CNS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639300     DOI: 10.1089/10430340360535751

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  20 in total

Review 1.  Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors.

Authors:  Devan L Puhl; Anthony R D'Amato; Ryan J Gilbert
Journal:  Brain Res Bull       Date:  2019-06-05       Impact factor: 4.077

2.  A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis.

Authors:  Srikanth Yellayi; Brendan Hilliard; Mustafa Ghazanfar; Akivaga Tsingalia; Michael H Nantz; Laura Bollinger; Fabian de Kok-Mercado; James G Hecker
Journal:  Mol Pharm       Date:  2011-07-19       Impact factor: 4.939

3.  Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery.

Authors:  Tsung-Yao Chang; Peng Shi; Joseph D Steinmeyer; Itthi Chatnuntawech; Paul Tillberg; Kevin T Love; Peter M Eimon; Daniel G Anderson; Mehmet Fatih Yanik
Journal:  Integr Biol (Camb)       Date:  2014-09-03       Impact factor: 2.192

Review 4.  Antioxidant enzyme gene transfer for ischemic diseases.

Authors:  Jian Wu; James G Hecker; Nipavan Chiamvimonvat
Journal:  Adv Drug Deliv Rev       Date:  2009-02-20       Impact factor: 15.470

5.  Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells.

Authors:  S Zou; K Scarfo; M H Nantz; J G Hecker
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

6.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

7.  Injectable Biodegradable Chitosan-Alginate 3D Porous Gel Scaffold for mRNA Vaccine Delivery.

Authors:  Jingxuan Yan; Ruying Chen; Hong Zhang; James D Bryers
Journal:  Macromol Biosci       Date:  2018-11-16       Impact factor: 4.979

8.  Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells.

Authors:  Ewa Grudzien-Nogalska; Jacek Jemielity; Joanna Kowalska; Edward Darzynkiewicz; Robert E Rhoads
Journal:  RNA       Date:  2007-08-24       Impact factor: 4.942

Review 9.  Intrathecal drug delivery in the era of nanomedicine.

Authors:  M J Fowler; J D Cotter; B E Knight; E M Sevick-Muraca; D I Sandberg; R W Sirianni
Journal:  Adv Drug Deliv Rev       Date:  2020-03-03       Impact factor: 15.470

10.  In vitro and in vivo gene therapy with CMV vector-mediated presumed dog beta-nerve growth factor in pyridoxine-induced neuropathy dogs.

Authors:  Jin Young Chung; Jung Hoon Choi; Il Seob Shin; Eun Wha Choi; Cheol Yong Hwang; Sang Koo Lee; Hwa Young Youn
Journal:  J Vet Sci       Date:  2008-12       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.